ストックスクリーナーアプリを入手
1.975
23.58%
0.385
前日終値:
$1.59
開ける：
$1.865
24時間の取引高:
3.50M
Relative Volume:
2.95
時価総額：
$238.13M
収益：
$257.24M
当期純損益:
$-237.89M
株価収益率:
-0.7596
EPS:
-2.6
ネットキャッシュフロー:
$-175.17M
1週間 パフォーマンス:
+22.81%
1か月 パフォーマンス:
+48.86%
6か月 パフォーマンス:
+100.80%
1年 パフォーマンス:
+53.52%
1日の値動き範囲:
$1.83
$2.00
1週間の範囲:
$1.5103
$2.00
52週間の値動き範囲:
$0.71
$2.00
Coherus Oncology Inc Stock (CHRS) Company Profile
名前
Coherus Oncology Inc
セクター
電話
(650) 649-3530
住所
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.9701 | 192.18M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.49 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.36 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.82 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
366.97 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.70 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-04 | アップグレード | Maxim Group | Hold → Buy |
| 2024-08-16 | ダウングレード | UBS | Buy → Neutral |
| 2023-11-17 | 開始されました | Robert W. Baird | Outperform |
| 2023-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2023-07-24 | 開始されました | Citigroup | Buy |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2023-03-28 | アップグレード | UBS | Neutral → Buy |
| 2022-06-14 | 開始されました | UBS | Neutral |
| 2022-03-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 開始されました | BofA Securities | Neutral |
| 2020-04-17 | 開始されました | SunTrust | Buy |
| 2019-08-13 | 開始されました | Mizuho | Buy |
| 2019-08-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-02 | 繰り返されました | Maxim Group | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-07 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-28 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-09 | 繰り返されました | Maxim Group | Buy |
| 2017-08-08 | 繰り返されました | JP Morgan | Overweight |
| 2017-06-13 | 繰り返されました | Maxim Group | Buy |
| 2017-05-05 | 開始されました | BMO Capital Markets | Outperform |
| 2016-10-19 | 開始されました | Robert W. Baird | Outperform |
| 2016-09-07 | 開始されました | Maxim Group | Buy |
| 2016-07-27 | 開始されました | Citigroup | Buy |
| 2016-01-20 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Coherus Oncology Inc (CHRS) 最新ニュース
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Oppenheimer initiates Coherus Biosciences stock with Outperform rating By Investing.com - Investing.com Canada
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途资讯
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - The AI Journal
CHRS: Pivotal 2026 data readouts expected for innovative oncology assets, with sales growth on track - TradingView — Track All Markets
January 2026 Penny Stock Spotlight: Three Promising Picks - simplywall.st
Can Coherus Oncology Inc. (8C5) stock survive global slowdownDividend Hike & Growth Focused Entry Reports - Улправда
There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise - simplywall.st
How Coherus Oncology Inc. (8C5) stock valuation compares with sectorOil Prices & Stepwise Swing Trade Plans - Улправда
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Biosciences Divests UDENYCA Business - MSN
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - FinancialContent
Coherus publishes data on tagmokitug antibody for cancer treatment By Investing.com - Investing.com Nigeria
Coherus (CHRS) Reports Promising Results for Anti-CCR8 Antibody in Cancer Treatment - GuruFocus
Coherus Oncology Introduces Tagmokitug: Promising Results from CCR8-targeting Antibody Research - Quiver Quantitative
Coherus publishes data on tagmokitug antibody for cancer treatment - Investing.com
Coherus Oncology Announces Publication in Molecular Cancer - GlobeNewswire
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) - Chartmill
What analysts say about Coherus Oncology Inc 8C5 stockMarket Insider Reports & Outstanding Growth Opportunities - earlytimes.in
Will Coherus Oncology Inc 8C5 stock outperform Dow Jones2025 Market Trends & Accurate Intraday Trading Signals - moha.gov.vn
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications (CHRS) - Seeking Alpha
Coherus Oncology, Inc.(NasdaqGM: CHRS) added to NASDAQ Biotechnology Index - marketscreener.com
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Coherus Oncology (CHRS) Price Target Increased by 13.33% to 5.78 - Nasdaq
Aug Shorts: How Coherus Oncology Inc. (8C5) stock valuation compares with sectorQuarterly Portfolio Review & AI Driven Stock Price Forecasts - Улправда
CEO Moves: How Coherus Oncology Inc. (8C5) stock valuation compares with sectorMarket Weekly Review & Risk Controlled Stock Pick Alerts - Улправда
Support Test: Can Coherus Oncology Inc. (8C5) stock survive global slowdownJuly 2025 Macro Moves & Smart Swing Trading Techniques - Улправда
Will Coherus Oncology Inc. (8C5) stock deliver stable dividends2025 Dividend Review & Breakout Confirmation Alerts - Улправда
CHRS: 2026 will be pivotal with major data readouts for novel immuno-oncology therapies - TradingView — Track All Markets
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving AverageTime to Sell? - MarketBeat
Coherus Oncology Earnings Notes - Trefis
LOQTORZI plus chemotherapy shows 31-month survival benefit in cancer study - Investing.com Australia
Coherus BioSciences stock jumps after positive cancer drug survival data By Investing.com - Investing.com UK
Coherus BioSciences stock jumps after positive cancer drug survival data - Investing.com
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - The Manila Times
Coherus Oncology (CHRS) price target decreased by 11.77% to 5.10 - MSN
Why Coherus Oncology Inc. (8C5) stock stays on top picksTrade Risk Summary & Daily Technical Forecast Reports - Newser
Why global investors buy Coherus Oncology Inc. (8C5) stockJuly 2025 Earnings & Expert Verified Movement Alerts - Newser
Does Coherus Oncology Inc. (8C5) stock trade below intrinsic valueMarket Volume Summary & Community Consensus Stock Picks - Newser
Why Coherus Oncology Inc. (8C5) stock could rally strongly2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - Newser
Can Coherus Oncology Inc. (8C5) stock sustain free cash flow2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Coherus Oncology, Inc. (NASDAQ:CHRS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Can Coherus Oncology Inc. (8C5) stock hold up in economic slowdownTrade Risk Assessment & Fast Gain Stock Tips - Newser
How strong is Coherus Oncology Inc. (8C5) stock earnings growthAnalyst Downgrade & Safe Entry Zone Identification - Newser
Coherus Oncology (CHRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Coherus Oncology Inc (CHRS) 財務データ
収益
当期純利益
現金流量
EPS
1.52%
0.73%
大文字化:
|
ボリューム (24 時間):